Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel + gemcitabine in advanced NSCLC with ECOG 2
2008-000653-36Phase 2Terminated
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- May 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and gemcitabine in non-small cell lung cancer (NSCLC), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Number of completed cycles of chemotherapy. Started May 2008; status: terminated.
02
Drugs
docetaxelgemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2008-000653-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000653-36.